News and Stories About Know Your Tumor
2018 Year in Review: Progress in Research, Part 1
Editor’s note: Welcome to the first article in our 2018 Year in Review series! Over the next couple weeks, we’ll […]
READ MORE
PanCAN Joins National Summit on Patient Advocacy
All cancer patients deserve the best care available, but not all can receive it. For some, the problem is financial. […]
READ MORE
New Cancer Drug Approved Based on Molecular Profiling
The U.S. Food and Drug Administration (FDA) approved Vitrakvi® (larotrectinib) today for the treatment of any locally advanced or metastatic solid tumor, […]
READ MORE
PanCAN’s President and CEO Featured at People v. Cancer Event
The Atlantic’s People v. Cancer event took place Nov. 14, 2018, in New York City. The event featured a stellar […]
READ MORE
‘Contacting PanCAN Was the Best Thing I Did’
After more than a year and a half of abdominal pain and digestive issues, Gail Bamer was diagnosed with stage […]
READ MORE
Ask Patient Central: Molecular Profiling
The Pancreatic Cancer Action Network (PanCAN) offers an Ask Patient Central series to provide helpful tips and information about commonly […]
READ MORE
1,000th Patient Receives Know Your Tumor® Report
The Pancreatic Cancer Action Network (PanCAN) has now delivered personalized molecular profiling reports to 1,000 pancreatic cancer patients through its […]
READ MORE
Persistence, Precision Medicine Pay off for Pancreatic Cancer Patient
When doctors told David Watson of Santa Monica, Calif., that he had type 2 diabetes in November 2016, he couldn’t […]
READ MORE
What Are Pancreatic Cancer Biomarkers?
A biomarker is a substance found in the body that can be measured. The amount of a biomarker may vary […]
READ MORE
What You Need to Know About Genetic and Molecular Testing
Editor’s note: Knowledge is power, but keeping up with all the different types of genetic and molecular tests and profiling […]
READ MORE
PanCAN Publishes Hopeful Precision Medicine Results
Published today in the esteemed Clinical Cancer Research, a journal of the American Association for Cancer Research, the Pancreatic Cancer […]
READ MORE
Institution’s Molecular Profiling Results Affect Clinical Decisions
Every pancreatic tumor is different. The Pancreatic Cancer Action Network (PanCAN) strongly recommends molecular profiling of your tumor to help […]
READ MORE
PanCAN President and CEO Shares Highlights from Esteemed Precision Medicine Roundtable
Editor’s note: Pancreatic Cancer Action Network (PanCAN) President and CEO Julie Fleshman attended the Harvard Business School (HBS) Kraft Precision […]
READ MORE
Precision Medicine Highlighted in the News
“All Cancer Patients Should Have Access To Genomic Testing” is the title of a compelling article featured in Forbes earlier […]
READ MORE
PanCAN’s Precision Medicine Results Featured at Major Meeting
The 2018 Gastrointestinal (GI) Cancers Symposium is taking place in San Francisco, Jan. 18 to 20. The meeting brings together […]
READ MORE
Largest Gift in PanCAN History Is a Powerful Testament to Donor’s Commitment to Innovation, Impact
Entrepreneur Skip Viragh was a collaborator. An innovator. A proactive problem-solver. A masterful leader. And he deeply valued these qualities […]
READ MORE
Keytruda Drug Is Science Breakthrough of the Year Runner-up
At the end of every year, Science magazine announces a Breakthrough of the Year – a discovery that revolutionized the […]
READ MORE
Discovery of Rare Mutation Gives Survivor Options, Hope
Akshay Mehta, MD, was in the middle of performing an orthopedic surgery when his first pancreatic cancer symptom arose. “I […]
READ MORE
Pancreatic Cancer in U.S. News & World Report
“Let’s face it: The pancreas is a behind-the-scenes organ most of us don’t know – or think – much about. […]
READ MORE
Thank You to PanCAN Scientists!
It’s Thank a Scientist Week! This seems like the perfect opportunity to show appreciation for a few PanCAN employees who […]
READ MORE
Progress Report: ‘Research Continues to Be Our Best Defense Against Cancer’
The American Association for Cancer Research (AACR) released its annual Cancer Progress Report earlier this week. “Research continues to be […]
READ MORE
Recent Precision Medicine Developments Showing Promise of Field
May was a busy month for pancreatic cancer precision medicine developments. Every pancreatic tumor is different. The Pancreatic Cancer Action […]
READ MORE
Know Your Tumor® Gives Survivor More Options, Time to Experience More Blessings
Josephine Scivoli’s oncologist tells her she’s an inspiration, a miracle. Her husband, John, agrees. “She definitely has a lot of […]
READ MORE
The Road to Effective Immunotherapy for Pancreatic Cancer Patients
Last week, we shared the exciting news that an immunotherapy agent, Keytruda, was the first drug approved by the FDA […]
READ MORE
Unprecedented Drug Approval Can Benefit Pancreatic Cancer Patients
For the first time, the U.S. Food and Drug Administration (FDA) has approved a cancer drug based only on molecular […]
READ MORE
Rare but Targetable Genetic Change Discovered in Pancreatic Cancer Patients
The Pancreatic Cancer Action Network’s state-of-the-art Know Your Tumor® precision medicine service offers molecular profiling to eligible patients. Molecular profiling […]
READ MORE
5 Things to Know About Precision Medicine
Precision medicine is a hot topic right now, but what does the phrase even mean? In short, with precision medicine, […]
READ MORE
Pancreatic Cancer Action Network’s Know Your Tumor Program Surpasses 1,000 Enrolled Patients
Pancreatic Cancer Action Network’s Know Your TumorSM Program Surpasses 1,000 Enrolled Patients MANHATTAN BEACH, Calif. – (Feb. 8, 2017) – The […]
READ MORE
Leading Oncologist Champions Treatment Progress Through Personalized Medicine
Dr. Andrew E. Hendifar, the medical oncology lead for the gastrointestinal disease research group at Cedars-Sinai Medical Center, champions progress […]
READ MORE
Study Shows Biomarker-Based Treatment Provides Best Results
We’ve learned a lot about pancreatic cancer in recent years, and we now know that every patient’s cancer is different […]
READ MORE
